SOPHiA GENETICS (NASDAQ:SOPH) Sees Strong Trading Volume – Here’s What Happened

SOPHiA GENETICS SA (NASDAQ:SOPH) shares saw unusually-strong trading volume on Thursday. 1,175,730 shares changed hands during mid-day trading, an increase of 275% from the previous session’s volume of 313,782 shares. The stock last traded at $7.27 and had previously closed at $7.06.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on SOPH. BTIG Research lifted their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of SOPHiA GENETICS in a research report on Monday. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, SOPHiA GENETICS currently has an average rating of “Hold” and a consensus price target of $10.00.

SOPHiA GENETICS Trading Up 3.0%

The company has a 50 day moving average of $7.97 and a 200 day moving average of $6.22. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The firm has a market cap of $609.88 million, a price-to-earnings ratio of -6.33 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The company had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. As a group, research analysts anticipate that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Insiders Place Their Bets

In related news, insider Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $7.26, for a total transaction of $36,300.00. Following the completion of the transaction, the insider directly owned 195,993 shares of the company’s stock, valued at $1,422,909.18. This trade represents a 2.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Chairman Jurgi Camblong sold 8,500 shares of the business’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $7.26, for a total transaction of $61,710.00. Following the completion of the transaction, the chairman owned 3,387,150 shares in the company, valued at approximately $24,590,709. This trade represents a 0.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 300,043 shares of company stock worth $2,256,756 in the last quarter. 4.88% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Maven Securities LTD bought a new position in SOPHiA GENETICS in the 2nd quarter valued at $866,000. AXQ Capital LP bought a new stake in shares of SOPHiA GENETICS during the second quarter worth $119,000. AWM Investment Company Inc. bought a new stake in shares of SOPHiA GENETICS during the second quarter worth $9,809,000. Hennion & Walsh Asset Management Inc. bought a new stake in shares of SOPHiA GENETICS during the second quarter worth $567,000. Finally, Royal Bank of Canada increased its stake in shares of SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after buying an additional 18,781 shares in the last quarter. Institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.